Esteya is the non-invasive solution for treating skin cancer. As treatment times are only two to three minutes per visit, Esteya can be a great option for patients with an active lifestyle.
Radiation therapy, particularly highly focused, High Dose Rate (HDR) brachytherapy, due to its proven efficiency and precision can be an appropriate option for treating non-melanoma skin cancer.1,2
HDR brachytherapy is a well-established technique with a history of outstanding results and excellent patient tolerance. A new brachytherapy solution, electronic brachytherapy, promises an even more refined and elegant approach to treating skin cancer.
In electronic brachytherapy, a small high dose rate x-ray source is used to apply radiation directly to the cancerous site. By virtue of this direct delivery, electronic brachytherapy can concentrate more therapeutic radiation on the disease target and less radiation to surrounding healthy tissue and organs. This makes it especially well-suited for treating skin lesions, such as basal cell or squamous cell carcinomas.
Electronic brachytherapy features radiation shielding requirements comparable to low voltage therapeutic x-ray devices and presents no challenges for handling radio-isotopes. This allows the system to be used in a much wider range of environments than traditional high dose rate (HDR) brachytherapy products.
 Alam M et al., The use of brachytherapy in the treatment of non-melanoma skin cancer: a review. J Am Acad Dermatol. 2011 Aug; 65(2):377-88.
 Tormo A et al. Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes. J Contemp Brachytherapy 2014 Jun; 6(2): 167–172.
Esteya gives patients and the healthcare team an effective and non-invasive alternative to surgery for treating skin cancer: electronic brachytherapy. Esteya provides a targeted, yet gentle skin cancer treatment: a precise high dose radiation to the cancerous site, minimized radiation to healthy tissue and a reduced chance of scarring. Because the treatment is short and gentle, patients can expect a short recovery period and may return to their normal routine quickly.
Esteya is especially beneficial in treating cosmetically challenging areas, such as the nose, lips, cheeks, temples and fingers, and for areas prone to wound closure problems, such as the scalp. Esteya may also be the preferred option for patients for whom surgery presents a high intra-operative or post-operative risk of complications.
Esteya provides an elegant approach for treating skin cancer, featuring the right size and portability to be used anywhere in the clinic.
Over the last three decades, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. Increasing numbers of new cases of basal cell and squamous cell carcinomas are diagnosed every year2.
Surgery is a very effective skin cancer treatment, and is the most commonly selected therapy among patients. Some patients, however, would like to have another option due to concerns about scarring in certain highly visible areas of skin, such as the face or hands. Similarly, some physicians may opt for a different treatment if they anticipate a challenging wound closure.
In some cases radiation therapy is an appropriate and effective option3, particularly highly focused, high dose rate (HDR) radiotherapy techniques. A well-established technique, HDR brachytherapy has accumulated outstanding results and excellent patient tolerance4. A new brachytherapy solution — electronic brachytherapy — promises an even more refined, elegant approach for treating skin cancer.
 Stern RS. Prevalence of a history of skin cancer in 2007: results of an incidence-based model. Arch Dermatol. 2010 Mar; 146(3):279-82
 Donaldson MR and Coldiron BM. No End in Sight: The Skin Cancer Epidemic Continues, Semin Cutan Med Surg. 2011 Mar; 30(1):3-5.
 Alam et al. The use of brachytherapy in the treatment of non-melanoma skin cancer: A review. J Am Acad Dermatol 2011, Volume 65, Number 2: 377-388
 Tormo et al. Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes. J Contemp Brachytherapy 2014; 6, 2: 167–172
Please find a selection of key publications and ongoing research in the brachytherapy arena with links directing you to the article source, e.g., PubMed and clinicaltrials.gov. This selection is made by Elekta and will be regularly updated with relevant new publications. Please note that this is only a partial list of publications
Electronic brachytherapy for superficial and nodular basal cell carcinoma: a report of two prospective pilot trials using different doses
J Contemp Brachytherapy. Jan; 8(1):1-8
Efficacy and safety of electronic brachytherapy for superficial and nodular basal cell carcinoma.
J Contemp Brachytherapy. Jun; 7(3):231-8
Dosimetric characteristics of a new unit for electronic skin brachytherapy
J Contemp Brachytherapy 2014; 6, 1
Non-melanoma skin cancer treated with electronic brachytherapy: Results at 1 year
Interventions for basal cell carcinoma of the skin
The Cochrane database of systematic reviews
Interventions for non-metastatic squamous cell carcinoma of the skin
The Cochrane database of systematic reviews
Esteya Electronic Brachytherapy
A Dedicated Solution for Improving Skin Cancer Patient Care
HDR brachytherapy for superficial non-melanoma skin cancers
Journal of medical imaging and radiation oncology
The use of brachytherapy in the treatment of non-melanoma skin cancer: a review
Journal of the American Academy of Dermatology
High dose rate brachytherapy with surface applicators: Treatment for non-melanoma skin cancer
Journal of Clinical Oncology
Non-melanoma skin cancer treated with HDR Valencia applicator: clinical outcomes.
J Contemp Brachytherapy 2014; 6, 2: 167–172
Complete response of endemic Kaposi sarcoma lesions with high-dose-rate brachytherapy: Treatment method, results, and toxicity using skin surface applicators
The indications for and results of HDR afterloading therapy in diseases of the skin and mucosa with standardized surface applicators
Radiotherapy and Oncology
The guidelines for treatment of non-melanomatous skin cancer are
Elekta is working side by side with hospitals to obtain the latest patients study data. Please view the case report from University and Polytechnic Hospital La Fe, in Valencia, Spain.
Images and patient case courtesy of University Hospital La Fe, Valencia 2014.
Results and outcomes of this patient case should not be interpreted as a guarantee of similar results.
Individual results may vary depending on circumstances and the patient’s condition. — See more at: What is Esteya?